Skip to main content

Table 4 Cox regression analysis for overall survival (OS), progression-free survival (PFS), and AML transformationa

From: The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts

  OS PFS AML transformation
HR 95 % CI P HR 95 % CI P HR 95 % CI P
Age (years) 1.029 0.987–1.073 0.174 1.039 0.996–1.084 0.074 1.007 0.952–1.064 0.819
Sex (male vs. female) 0.711 0.298–1.695 0.442 0.881 0.388–1.999 0.761 0.823 0.266–2.553 0.737
IPSS-R total score 1.634 1.263–2.115 <0.0001 1.546 1.214–1.969 <0.0001 1.699 1.200–2.405 0.003
SF3B1b (mut vs. WT) 2.663 0.572–12.397 0.212 1.533 0.193–12.145 0.686    
U2AF1 (mut vs. WT) 1.648 0.365–7.436 0.516 4.840 1.655–14.157 0.004 1.252 0.149–10.494 0.836
SRSF2 (mut vs. WT) 1.216 0.270–5.485 0.799 4.379 1.604–11.952 0.004 2.672 0.697–10.245 0.152
  1. Statistical significance is indicated in boldface type
  2. aMultivariate analysis of OS, PFS, and AML transformation was performed using a Cox proportional hazards regression model that included age, sex, IPSS-R total score, and mutation status of SF3B1, U2AF1, and SRSF2
  3. bFor SF3B1mut patients, no AML transformation was seen
  4. AML, acute myeloid leukemia; CI, confidence interval; HR, hazard ratio; IPSS-R, revised International Prognostic Scoring System; mut, mutated; WT, wild-type